The synthetic human growth hormone fragment (32-38) increases glucose uptake in the conscious dog.

Abstract

hGH32-38 was tested to determine if the peptide could affect hepatic glucose production in the conscious dog under basal conditions (euglycemia) or if it could enhance glucose uptake when hyperglycemia was induced. hGH32-38 (1.6 nmol.kg-1.min-1) or vehicle was infused in a cross-over design study into each of 4 conscious 16 h-fasted dogs for 3 h (0-180 min) following a 40 min control period. At 90 min, plasma glucose was raised to and maintained at 9.4 mmol/l by glucose infusion for 3 h (until 270 min). Neither hGH32-38 nor vehicle infusion had a significant effect on insulin and glucagon levels or on tracer determined [( 3-3H]glucose) glucose production. As a result, neither treatment changed plasma glucose (5.72 +/- 0.17 to 5.78 +/- 0.17 mmol/l with hGH32-38; 5.50 +/- 0.22 to 5.50 +/- 0.17 mmol/l with vehicle). Induction of hyperglycemia (9.4 mmol/l) caused glucagon concentrations to fall similarly to about 50 ng/l with and without hGH32-38. Insulin rose to similar levels in both protocols, yet more glucose was required to maintain the same hyperglycemia with hGH32-38 (135-180 min) (74.9 +/- 12.7 vs 43.7 +/- 7.1 mumol.kg-1.min-1, P less than 0.05). In summary, hGH32-38 significantly increased glucose disposition during hyperglycemia and this effect may be attributed to enhanced insulin action or to an insulin independent action of the peptide.